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METHODOLOGY
Synthesis of europium-doped VSOP, 
customized enhancer solution and improved 
microscopy fluorescence methodology 
for unambiguous histological detection
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Abstract 
Background: Intrinsic iron in biological tissues frequently precludes unambiguous the identification of iron oxide 
nanoparticles when iron‑based detection methods are used. Here we report the full methodology for synthesizing 
very small iron oxide nanoparticles (VSOP) doped with europium (Eu) in their iron oxide core (Eu‑VSOP) and their 
unambiguous qualitative and quantitative detection by fluorescence.
Methods and results: The resulting Eu‑VSOP contained 0.7 to 2.7% Eu relative to iron, which was sufficient for fluo‑
rescent detection while not altering other important particle parameters such as size, surface charge, or relaxivity. A 
customized enhancer solution with high buffer capacity and nearly neutral pH was developed to provide an antenna 
system that allowed fluorescent detection of Eu‑VSOP in cells and histologic tissue slices as well as in solutions even 
under acidic conditions as frequently obtained from dissolved organic material. This enhancer solution allowed detec‑
tion of Eu‑VSOP using a standard fluorescence spectrophotometer and a fluorescence microscope equipped with a 
custom filter set with an excitation wavelength (λex) of 338 nm and an emission wavelength (λem) of 616 nm.
Conclusion: The fluorescent detection of Eu‑doped very small iron oxide nanoparticles (Eu‑VSOP) provides a 
straightforward tool to unambiguously characterize VSOP biodistribution and toxicology at tissue, and cellular levels, 
providing a sensitive analytical tool to detect Eu‑doped IONP in dissolved organ tissue and biological fluids with 
fluorescence instruments.
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Background
The development of iron oxide nanoparticles (IONP) 
[1–9] as contrast agents for magnetic resonance imag-
ing (MRI) [10, 11] started about 4 decades ago. How-
ever, IONP that had early been approved by the US Food 
and Drug Administration (FDA) for liver imaging such 
as Endorem/Feridex® (AMAG Pharmaceuticals, Inc., 
Walthman, MA, USA) [12] and  Resovist®; (Schering 
AG-now Bayer Pharma AG, Berlin, Germany) [13] have 
not been further developed or have been withdrawn from 
the market [14–16]. IONP was slowed down by the fast 
establishment of gadolinium-based contrast agents for 
clinical MRI and first-pass arterial MRI angiography [17]. 
Recently, the safety concerns raised against some gado-
linium-based contrast agents (GBCA) [18] have moti-
vated new attempts at off-label clinical used of magnetic 
IONP such as ferumoxytol [19, 20]. Initially developed 
to treat iron anemia [21, 22], ferumoxytol/feraheme® is 
highly suitable for T1- and T2-weighted MRI. Besides the 
use of IONP in MRI, the emerging technique of magnetic 
particle imaging (MPI) requires the development of new 
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superparamagnetic IONP [23]. Therefore, the develop-
ment of iron oxide-based contrast agents remains a topic 
of high experimental and clinical relevance.
Very small iron oxide particles (VSOP), with a hydro-
dynamic diameter of 7 nm, combine high cellular uptake 
with low cytotoxicity due to their biocompatible citrate 
coating [24–28]. Earlier versions of these IONP, pro-
duced as VSOP-C184 (Ferropharm, Teltow, Germany) 
[29], were developed to the level of phase I and II as 
blood pool contrasts agent for MR angiography [30–32], 
but they are no longer available from the company. In 
the last decade, the synthesis of VSOP has been refined 
in our laboratory, and VSOP have been explored for vas-
cular imaging [32, 33] and other applications such as 
assessment of myocardial inflammation [34], sensitive 
detection of blood–brain barrier alterations [35], in vivo 
tracking of monocyte migration after intracerebral injec-
tion [36], and discrimination of different inflammatory 
events in an animal model of multiple sclerosis [37]. 
Early studies recognized VSOP accumulation in athero-
sclerotic lesion, 1 h after IV injection in rabbits [38], as 
opposed to 3  days required for accumulation of feru-
moxytol in atherosclerotic lesions, in hyperlipidemic rab-
bits [39]. Recently, the potential of VSOP [38, 40–43] and 
other IONP for atherosclerotic plaques characterization 
has been explored [44, 45].
Further developed IONP such as VSOP require detec-
tion tools for their in  vitro characterization, e.g., tissue 
localization, biodistribution, toxicology, and stability. 
Bimodal contrast agents for MR and fluorescence imag-
ing are commonly produced by functionalization of the 
IONP coating with fluorescent dyes [46–48]. However, 
a major drawback of this method, especially for small 
IONP like VSOP, is the possibility that modifications of 
IONP coating could alter the particle’s pharmacokinetic 
bahavior, cause in  vivo IONP degradation, and lead to 
loss of the fluorescent dye [49].
An alternative to functionalization of the IONP coat is 
iron oxide core functionalization by intercalation of lan-
thanide ions for example [50] and detection of the inter-
calated lanthanide to identify the localization of IONP in 
tissues. A method of magnetite core dotation with lan-
thanides was first described for dextran-coated ultras-
mall mixed ferrite iron oxides (USMIOs) [51].
Here we used europium (Eu) to intercalate it into the 
core of VSOP to develop Eu-VSOP. Europium is a lantha-
nide (Ln) that does not occur physiologically and is not 
used in drugs, and therefore is not, normally present in 
biological systems. Early europium toxicological stud-
ies in rats showed that europium salts had no effect on 
rat growth, complete blood count, or organ function 
after being included in the food at concentrations of up 
to 1%  EuCl3 over 12 weeks [52, 53]. However, possible Eu 
release from VSOP needs to be ruled out to avoid safety 
issues as currently discussed for gadolinium [54–57]. 
VSOP without europium doping should be used in future 
clinical applications. Furthermore, the direct excitation 
of lanthanides for fluorescent detection is ineffective, 
because the 4f–4f electronic transitions in  Ln3+ ions are 
forbidden by the electronic dipole selection rules, lead-
ing to very low molar extinction coefficients. A solu-
tion to this is the use of an antenna system—an organic 
chromophore and chelator—that coordinates the  Ln3+ 
ion, changing the symmetry of the orbitals, and trans-
fers the energy required for fluorescence excitation to the 
lanthanide [58]. Additionally, europium chelates exhibit 
large Stokes shifts (280  nm) and narrow emission spec-
tra, which ensure optimal fluorescent detection with high 
specificity.
We recently reported accumulation of Eu-VSOP in 
atherosclerotic plaques of an  ApoE−/− mice model, high-
lighting the relevance of unambiguous detection of iron 
oxide nanoparticles. Detection of these IONP in tissues 
is routinely done by iron staining (Perl’s stain), which, 
however, does not consistently discriminate intrinsic iron 
from IONP iron (VSOP) [41]. In that study, we showed 
unambiguous detection of Eu-VSOP in tissues by quan-
titative spatial detection of europium using laser abla-
tion inductively coupled plasma mass spectrometry 
(LA-ICP-MS) [59]. Previously, our group demonstrated 
higher sensitivity of Eu-VSOP fluorescence detection in 
solution compared with the phenanthroline iron detec-
tion method [60]. We present the complete synthesis of 
citrate-coated very small iron oxide nanoparticles and 
the procedure for stably intercalating  Eu3+ into their iron 
oxide core to produce Eu-VSOP. In addition, we prepared 
a customized enhancer solution (histo-Eu-enhancer) with 
neutral pH and increased buffer capacity, and improved 
the fluorescence methodology to achieve sensitive and 
stable detection of Eu-VSOP in cells and histological tis-
sue sections. Overall, we show here that Eu-VSOP can 
now also be imaged by fluorescence microscopy and 
quantitatively determined by widely available fluores-
cence spectrophotometers.
Methods
Nanoparticle synthesis
Synthesis of the citrate-coated very small iron oxide nan-
oparticle (VSOP) and europium-doped citrate-coated 
VSOP (Eu-VSOP) was performed according to the 
method of Goodarzi et al. [61].
VSOP
27.3 g (100 mmol) iron(III) chloride hexahydrate (Sigma-
Aldrich, USA) and 14.0  g (70  mmol) iron(II) chloride 
tetrahydrate (Sigma-Aldrich, USA) were successively 
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dissolved in water (200  mL) at 0  °C. Ammonia solution 
(90  mL) (28.0–30.0%, Sigma-Aldrich, USA) was added 
under vigorous stirring. The resulting black suspen-
sion was stirred for further 30  min at 0  °C. After mag-
netic separation, the supernatant was removed, leaving a 
residue of 100 mL. 300 mL of citric acid (Sigma-Aldrich, 
USA) solution c(C6H8O7)  =  0.348  mol/L was added 
under stirring and heated to 80–90 °C for 60 min. After 
a further magnetic separation, the supernatant was sepa-
rated, centrifuged, washed, and concentrated to 100 mL 
by ultrafiltration with a 100 kD (PES) Vivaflow filter (Sar-
torius, Göttingen, Germany) until the filtrate was color-
less. Then 100 mL water and 1 mL of a saturated sodium 
chloride (Merck, Germany) solution was added and the 
pH adjusted to 5.5 with citric acid. The solution was again 
concentrated to 100 mL and washed with water until the 
conductibility of the filtrate was lower than 10  μS. This 
procedure was repeated three times, and finally the solu-
tion was concentrated to 50 mL.
Dotation of VSOP with Europium (Eu‑VSOP‑1 to Eu‑VSOP‑7)
Different amounts of europium(III) chloride hexahy-
drate (Sigma-Aldrich, USA) were added to synthesized 
VSOP (0.236  g for Eu-VSOP-1; 0475  g for Eu-VSOP-2; 
0.706 g for Eu-VSOP-3; 0.880 g for Eu-VSOP-4; 1.185 g 
for Eu-VSOP-5; 1.77 g for Eu-VSOP-6; and 2.37 g for Eu-
VSOP-7). The europium chloride needs to be dissolved 
after the iron(III) chloride has been dissolved to ensure 
sample homogeneity. Once the europium(III) chloride is 
completely dissolved, the iron(II) chloride can be added.
Chemical characterization of the nanoparticles
Nanoparticle iron quantification
The iron concentration of synthesized Eu-VSOP was 
determined using the phenanthroline method [62, 63]. 
In short, 5  mL hydrochloric acid (Sigma-Aldrich, USA) 
(c(HCl) =  6  mol/L) were added to 0.5  mL of the nano-
particle solution and dissolved under heating (60  °C) 
for 20  min. The solution was then diluted to a total of 
50  mL with water (stock solution). 1  mL of the stock 
solution was diluted to a total of 25 mL with water. The 
diluted solution (2  mL) was used to develop the phen-
anthroline reaction by mixing it with 1  mL of hydroxy-
lamine hydrochloride (Sigma-Aldrich, USA) solution 
w(NH2OH·HCl)  =  10% and 7  mL of the phenanthro-
line hydrochloride solution (1.0  g 1,10-phenanthroline 
hydrochloride (Merck, Germany), 14.0  g acetic acid 
w(CH3COOH)  =  99–100% (Sigma-Aldrich, USA) and 
21.7  g sodium acetate trihydrate (Carl Roth, Germany) 
dissolved in water to 1  L). The developed colorimet-
ric reaction was photometrically measured after 15 min 
incubation at room temperature (RT) at 510  nm in 
a SPECORD 205 spectrophotometer (Analytik Jena, 
Germany) using the Win ASPECT software (Version 
2.1.1.0).
As reference, 2  mL of iron standard solution 
(1000  mg/L  ±  0.2%, Carl Roth, Germany) were diluted 
with water to 100 mL. This diluted solution (2 mL) was 
mixed with 1  mL of hydroxylamine hydrochloride solu-
tion (w(NH2OH·HCL)  =  10%) and 7  mL of the phen-
anthroline hydrochloride solution and also measured at 
510 nm.
Nanoparticles size
Nanoparticles size was measured by dynamic light scat-
tering at a Zetasizer Nano ZS (Malvern Instruments Ltd., 
Worcestershire, UK) equipped with the Zetasizer Soft-
ware Version 6.20. The samples were diluted with HEPES 
(Sigma-Aldrich, USA) solution c(HEPES) =  10  mmol/L 
(pH = 7.4) to a final iron concentration of 1 mmol/L.
Mean iron core sizes and magnetite/maghemite struc-
ture of IONP was confirmed by transmission electron 
microscopy (TEM). TEM examinations were performed 
by the Zentraleinrichtung Elektronenmikroskopie 
(ZELMI) at the Technical University Berlin. High-reso-
lution transmission electron microscopy (HRTEM) using 
a TECNAI G2 20 S-Twin (FEI-Company, Hillsboro OR, 
USA) was used with accelerating voltage of 200 kV and a 
300 mesh Cu-grid (Fig. 1).
Magnetic characterization of VSOP and Eu‑VSOP
All measurements were performed at 40 °C and 40 MHz 
(0.94 T) using an MR spectrometer (Minispec mq 
40; Bruker Karlsruhe, Germany). Diluted nanoparti-
cle solutions with iron concentrations between 0.1 and 
1.5  mmol/L were prepared. Three solutions with differ-
ent concentrations were measured for each sample. The 
relaxation coefficients  R1 and  R2 were obtained by linear 
fitting of  T1 and  T2 relaxation rates, and values were nor-
malized to the iron concentrations.
Enhancer solution for histological use
Enhancer solutions following the principle described by 
Hemmilä et  al. [64] are commercially available for fluo-
rescent detection of Europium with analytical purposes.
We tested the  DELFIA® enhancer solution (Perkin 
Elmer) (pH 2.5) but found it to be of limited use for 
detecting the fluorescent signal of Eu-VSOP, and there-
fore we produced a customized enhancer solution with 
improved buffer capacity (pH 6.6) to allow the detection 
of Eu fluorescence under physiological pH conditions 
and a comparative study is presented below.
The customized histo-Eu-enhancer (HEE) was pre-
pared with the same antenna system as used by the 
 DELFIA® enhancer solution (Perkin Elmer) with a modi-
fied dihydrogen phosphate-hydrogen phosphate buffer 
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system. This antenna is formed by the ligands β-NTA and 
TOPO molecules that coordinate the europium ion local-
ized in the core. This complex is surrounded by Triton 
X-100, forming a micelle-like structure (Additional file 1: 
Figure S1).
To prepare the solution, first 8.640  g (0.072  mol) 
sodium phosphate monobasic (Sigma-Aldrich, USA) and 
7.506  g (0.053  mol) sodium phosphate dibasic (Sigma-
Aldrich, USA) were dissolved in 600  mL water, which 
was followed by addition under stirring of 1.25 mL Tri-
ton X-100 (Sigma-Aldrich, USA), 5  mg (18.8  μmol) 
4,4,4-Trifluor-1-(2-naphthyl)-1,3-butadione (β-NTA) 
(Sigma-Aldrich, USA), and 24.2  mg (62.5  μmol) Tri-n-
octylphosphine oxide (TOPO) (Sigma-Aldrich, USA). 
The mixture was sonicated at 600  W for 30  min, filled 
up to 1 L and sonicated once more for 100  min. This 
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Fig. 1 Transmission electron microscopy (TEM) images show monocore structure and mean iron core sizes of approx. 5–7 nm for VSOP (a), Eu‑
VSOP‑4 (b), and Eu‑VSOP‑7(c). Selected areas of electron diffraction (SAED) pattern (d–f) confirms the magnetite/maghemite structure and percent‑
age of IONP as distributed by size (g–i). Scale bar a–c: 20 nm; scale bar d–f: 2 nm−1
0 20 40 60 80 100
0
200
400
600
800
1000
HEE DELFIA Enhancer
c(Eu)/(nmol/L)F
lu
or
es
ce
nc
e 
[A
rb
itr
ar
y 
U
ni
ts
]
Fig. 2 Quantification of Eu fluorescence. Eu fluorescence signal 
intensity increased linearly with increasing Eu concentration with 
both enhancer solutions. Therefore, both systems are suitable for 
quantitative detection of  Eu3+ in solutions with neutral pH (n = 5). 
Regression analysis for HEE  (r2 = 0.9999) and for  DELFIA® (r2 = 0.9994)
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resulted in a modified enhancer solution termed ‘histo-
Eu-enhancer’ (HEE) with a pH of 6.6.
Quantification of europium fluorescence
All fluorescence acquisitions were performed on a 
Hitachi fluorescence spectrometer F-7000 with 338  nm 
excitation wavelength and 616  nm emission wavelength 
using a photo multiplier tube (PMT) at 400 V and a slit 
of 10 nm.
Eu fluorescence intensity was quantified with both 
enhancers using a Europium(III) standard solution 
(1001 ± 5 mg/L, Fluka, Swiss) diluted in water at a con-
centration range between 100 and 1000  nmol/L and 
mixed with the HEE (1:9) (Fig. 2). This solution was also 
used for calibration curves required to validate meas-
urements and compensate for variations which, as we 
observed, are unavoidable between devices and are also 
due to changes in the excitation lamp intensity. This cali-
bration curve was used to determine the europium con-
tent of the synthesized Eu-VSOP. Therefore, the Eu-VSOP 
were dissolved in hydrochloric acid c(HCL)  =  6  mol/L 
and then diluted with water until the europium concen-
tration was between 100 and 1000  nmol/L. The diluted 
solution (0.1 mL) was mixed with 0.9 mL of the enhancer 
solution and fluorescence was assessed as described.
The stability of the fluorescent compound (enhancer-
Eu-VSOP) is pH-dependent as described by Hemmilä 
[64]. Therefore, we performed Eu fluorescence quantifica-
tion in the presence of free ions present in organic solu-
tions such as  Ca2+ (not shown) and  Fe3+. Several  Eu3+ 
solutions with a constant concentration of Europium 
c(Eu)  =  500  nmol/L and different  Fe3+ concentrations 
in the range of 0.1 to 10,000  μmol/L were prepared. 
100 μl of these solutions were mixed with 900 μL of the 
enhancer solution, and fluorescence intensity measured 
with both enhancer solutions was compared for three 
independent samples (Fig. 3).
The fluorescence intensity of intact Eu-VSOP-7 was 
quantified independently with both enhancer solutions 
(HEE or  DELFIA®) and acquired every 2 min for 6 h for 
three different samples (Fig. 4).
Cellular uptake of Eu‑VSOP
The macrophage cell line RAW 264.7 (ATCC Cell Biol-
ogy Collection (Promochem LGC, Molsheim, France), 
derived from mice peritoneal macrophages and trans-
formed by the AMLV (Abelson Murine Leukemia Virus), 
was used. Cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, ATCC), supplemented with 
10% of fetal bovine serum (FBS, Gibco) and 1% penicil-
lin–streptomycin (penicillin 10,000 units/mL, streptomy-
cin 10 mg/mL; Sigma-Aldrich), at 37  °C in a 5% carbon 
dioxide humidified atmosphere. Cells were regularly pas-
saged before reaching confluence with medium change 
every 2 days.
To achieve cellular uptake of Eu-VSOP, macrophages 
were seeded at 40,000 cells/cm2 in six-well plates with 
growth medium (1.9  mL/well). The next day, cells were 
incubated for 24  h. Therefore, growth medium was 
replaced by IONP solution at 0.5 mmol/L iron concentra-
tion (VSOP, Eu-VSOP-3, or Eu-VSOP-7) in DMEM with-
out phenol red and 1% fetal bovine serum (FBS, Gibco) 
for cell synchronization [65]. Negative controls (empty 
cells) were prepared under the same conditions but in the 
absence of nanoparticles.
All cells were washed 3 times with PBS and passaged to 
remove nanoparticles that attached to plastic surfaces of 
the culture plates. For fluorescence assessment of euro-
pium, cells were passaged into adherent chamber slides 
(Thermo Fisher Scientific, Waltham, MA, USA) at 4000 
cells/cm2 for fluorescence microscopy (Fig. 5).
For population doubling time (PDT) quantification, 
cells were passaged into six-well plates at 1000 cells/cm2 
with complete growth medium and incubated for 8 days 
with medium exchange every 2 days. Every 2 days, cells 
were counted to determine the population doubling time 
(PDT =  T*n2/ln (A/A0): T =  time between cell counts, 
A =  final cell number,  A0 =  initial cell number) (Addi-
tional file 2: Figure S3).
Animal experiments
All experimental procedures were approved by the 
regional animal study committee of Berlin, the Lande-
samt für Gesundheit und Soziales Berlin (LAGeSo), and 
mice were acquired and handled in accordance with the 
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Fig. 3 Stability of Eu fluorescence in presence of free iron(III) ions. 
The fluorescence intensity developed by each enhancer solution 
was set to 100% for a solution with constant  cfinal(Eu) = 50 nmol/L 
and without iron(III). The fluorescence signal intensity developed 
by DELFIA was reduced to 10% when exposed to c(Fe) > 1 µmol/L 
while the Eu fluorescence intensity developed with HEE remained at 
100% in the presence of c(Fe) up to 100 µmol/L. The SD of the mean 
fluorescence signal (n = 3) for HEE variates between 0.7 and 8% and 
between 0.3 and 11% for  DELFIAⓇ
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guidelines published in the NIH Guide for the Care and 
Use of Laboratory Animals (NIH Publication No. 85–23, 
revised 1985). C57BL/6 mice were bred and maintained 
in the facilities of the “Forschungsinstitut für Experimen-
telle Medizin” (FEM, Charité—Universitätsmedizin, Ber-
lin, Germany) under specific pathogen-free conditions. 
Eu-VSOP was administered intravenously to 6–8-week-
old female mice at a dose of 0.2  mmol/kg. After 24  h, 
mice were processed for histology. Following termi-
nal anesthesia, mice were transcardially perfused with 
20 ml PBS, then with 20 mL zinc fixation solution (0.5% 
zinc acetate, 0.5% zinc chloride, 0.05% calcium acetate). 
Spleens were extracted and subsequently fixed in diluted 
zinc solution (1:10) for 3 days at room temperature.
Fluorescence detection of Eu‑VSOP in cells and tissue 
sections
Cells grown in chamber slides were washed 3 times 
with PBS before fixation with −  20° pre-cooled ace-
tone-methanol (1:1) for 20  min. Fixation solution was 
removed and wells were air-dried for 5 min. Pre-cooled 
enhancer solutions were kept at 4° in the dark. Either the 
 DELFIA® enhancer solution (PerkinElmer, Germany) or 
our customized HEE was added to the cells and incu-
bated in the dark for 10  min at RT. The enhancer solu-
tions were removed, slides were air-dried for 5 min in the 
dark and mounted with cover slips and  FluoromountTM 
mounting medium (Sigma-Aldrich Co, St Louis, MO, 
USA). Photomicrographs were taken 5 min, 30 min, and 
60  min later. Identical settings, e.g., light exposure time 
(10 s), were used for all chamber slides. Positions of fluo-
rescence photomicrographs were saved using the Zeiss 
microscope software for each slide and relocalized to 
determine iron co-localization of Eu-VSOP after Prus-
sian blue stain (Fig. 5).
Spleen tissue was dehydrated and embedded in paraf-
fin blocks according to standard procedures, and 5-μm 
sections were cut on a microtome. Tissue sections were 
then deparaffinized and re-hydrated. Fluorescent detec-
tion of Eu-VSOP was performed after tissue fixation and 
enhancer incubation as done with cells. Photomicro-
graphs were taken (see below) after enhancer removal 
and 60 min storage at RT in the dark as done with cells 
(Fig. 6).
Iron quantification in cells and tissue sections
Conventional detection of Eu-VSOP by Prussian blue 
staining (Perl’s method) was done by incubation of slides 
with 1% potassium hexacyanoferrate (II) solution for 5 
min and 1% potassium hexacyanoferrate with 1% HCL 
(20 min), followed by counterstain with nuclear fast red 
solution as described [66].
Microscopy and image analysis
Photomicrographs were obtained in an Axio Observer.
Z1 with AxioVision Software ZEN 2012 (Carl Zeiss AG. 
Oberkochen, Germany). Europium was detected with a 
customized filter set consisting of an excitation filter (BP 
350/50  nm), a beam splitter filter (380  nm LP), and an 
emission filter (HC 615/20  nm) (AHF Analysentechnik 
AG, Tübingen, Germany).
Several photomicrographs were taken for repeated 
cell uptake experiments (n = 5), exemplary photomicro-
graphs are shown (Fig. 5).
Chamber slides with RAW 264.7 cells used for fluo-
rescent detection of Eu-VSOP were washed overnight 
in Millipore water  (mH2O) to carefully remove cover 
slides and subsequently stained for iron. Photomicro-
graphs were taken using the coordinates stored by the 
microscope software. A slight difference in size between 
fluorescence and light microscopy images is due to the 
different resolution of fluorescence and light cameras 
(Fig. 5). Tissue sections were stained following the same 
protocol, and consecutive spleen slides were used for flu-
orescence and conventional iron detection of Eu-VSOP 
(Fig. 6).
ImageJ (National Institutes of Health, USA) was used 
to compare fluorescence intensity between photomicro-
graphs (ROIs: n = 10 per time point). White background 
was set to equal for all images to define regions of interest 
(ROI) for assessing mean fluorescence intensity (Fig. 5G).
Europium fluorescent signal intensity achieved with 
both enhancer solutions over time (5, 30, 60  min) was 
compared by two-way ANOVA analysis using the Graph-
pad Software (GraphPad Prism 5).
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Fig. 4 Fluorescence of Eu‑VSOP. Fluorescence intensity of doped 
Eu‑VSOP‑7 (60 nmol/L) increased over time (measured every 2 min 
for 6 h; n = 3) with the HEE solution, while it drastically decreased 
after ~ 2 h with the  DELFIA® enhancer solution. The SD of the mean 
fluorescence signal for HEE variates between 0.8 and 9.4% and 
between 0.84 and 5.86% for  DELFIA®
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Fig. 5 Fluorescent signal of Eu‑VSOP in cells. Eu‑fluorescent signal was successfully detected at 615/20 nm in macrophages labeled with Eu‑VSOP‑7. 
Eu‑fluorescence developed with customized HEE increased after 30 min, and remained similar after 60 min (E, F); while Eu‑fluorescence obtained 
with  DELFIA® enhancer was lower at 5 min, similar at 30 min, but significantly reduced after 60 min (A–C). This is corroborated by semiquantitative 
analysis of Eu fluorescence intensity for 10 regions of interest (ROI) done with ImageJ (G). P < 0.001 two‑way ANOVA. Scale bar: 100 µm
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Results
Synthesis and properties of the VSOP and Eu‑VSOP
Nanoparticle solutions of VSOP and Eu-VSOP prepared 
using the method described above are suspensions that 
remain stable for more than 2 years without precipitation 
when autoclaved and stored in sealed dark glass bottles 
(data not shown).
The amount of europium intercalating into the iron 
cores of VSOP (m(Eu):m(Fe) ratio) increased with 
the amount of Eu used in the synthesis. Thus, Eu-
VSOP-7 showed the highest amount of intercalated 
europium with m(Eu):m(Fe)  =  0.0274, which was 3.75 
times higher than that achieved for Eu-VSOP-1 with 
m(Eu):m(Fe) = 0.0073 (Table 1).
Transmission electron microscopy (TEM) images of 
VSOP, Eu-VSOP-4, and Eu-VSOP-7 confirmed the mag-
netite/maghemite structure and IONP mean iron core 
sizes of approx. 5 to 7 nm (Fig. 1).
Hydrodynamic diameters assessed by dynamic light 
scattering revealed a narrow distribution with mean 
values between 9.9  ±  2.1  nm for all Eu-VSOP and 
10.8 ± 2.8 nm for VSOP without intercalated Eu (Addi-
tional file 3: Table S1).
Furthermore, the magnetic properties (R1, R2 and MS) 
of VSOP decreased with increasing amounts of interca-
lated  Eu3+ (Table 2).
Quantification of europium
We observed that the fluorescence intensity developed 
by both the  DELFIA® and customized HEE enhancer 
solutions with free  Eu3+ ions is linear to the Eu concen-
tration [c(Eu)] and allows similar detection with free 
 Eu3+(Fig. 2).
Comparison of the fluorescence intensity developed by 
both enhancer solutions for a fixed amount of  Eu3+ and 
increasing amounts of free  Fe3+ ions revealed that the 
fluorescent signal rapidly decreased to 10% in the pres-
ence of c(Fe) higher than 1  µmol/L when the  DELFIA® 
enhancer (pH 2.5) was used. In contrast, the use of HEE 
resulted in stable fluorescence intensity (100%) with  cFe 
up to 100 µmol/L (Fig. 3). The standard deviation of the 
mean fluorescence signal is the highest (~  8% for HEE 
and 11% for  DELFIA® Enhancer) at the higher iron con-
centrations due to reducing fluorescence intensity values.
The fluorescence intensity developed with both 
enhancers for Eu-VSOP-7 was time-dependent. The Ini-
tial fluorescence intensity achieved with both enhancer 
solutions for Eu-VSOP-7 (Fig.  4) was lower than that 
achieved with free Eu ions at the same c(Eu) (60 nmol/L) 
(Fig. 2).
The maximum fluorescence intensity achieved with Eu-
VSOP-7 using  DELFIA® enhancer solution was observed 
after approximately 110 min and decreased continuously 
after approximately 2  h over the following 6  h. In con-
trast, the use of HEE resulted in a constant increase in 
fluorescence intensity for the entire 6-h period (Fig. 4).
The standard deviation of the mean fluorescence sig-
nal is higher (~  9.4% for HEE and 5.9% for  DELFIA® 
Enhancer) at the beginning of the reaction (up to 10 min) 
and is reduced at increasing reaction time (up to ~ 0.8% 
for both enhancers). This might be due to the kinetic 
of the reaction between the intercalating  Eu3+ and the 
antenna molecule of the enhancer.
Fluorescence detection of Eu‑VSOP in cells and tissue
Phagocytic RAW 264.7 macrophages efficiently take up 
both, VSOP and europium-doped Eu-VSOP. Uptake was 
observed to increase with VSOP loading concentrations 
(not shown) and incubation times (Additional file 2: Fig-
ure S3B, D). Ten-fold higher IONP uptake (10–13  pg 
Fe/cell) was reached for VSOP, Eu-VSOP-4, and Eu-
VSOP-7 after 24 h incubation in comparison to 4 h incu-
bation of an identical IONP incubation concentration 
 (cFe  =  0.5  mM). Four days after IONP uptake, labeled 
cells showed significantly increased PDT in comparison 
with non-labeled cells (Additional file  2: Figure S3C). 
However, similar PDT was observed 2  days after cell 
labeling despite a higher concentration of  cFe/cell than at 
day 4. Furthermore, the effect on PDT disappeared after 
complete dilution of the IONP load (Fe/cell) due to cell 
division (days 6 and 8) (Additional file 2: Figure S3D).
RAW 264.7 macrophages labeled during 24 h with Eu-
VSOP-7 were used to assess the fluorescence intensity 
signal of Eu-VSOP.
Fluorescence detection of Eu-VSOP was successful with 
cells, 10  min after incubation of Eu-VSOP-labeled cells 
with  DELFIA® and with the customized enhancer solu-
tion (HEE). However, fluorescence intensity increased 
with HEE over time (5, 30, and 60 min) after removal of 
the enhancer solution and mounting of the slides with 
cover slides at RT (Fig.  5).  DELFIA® and HEE enhanc-
ers reached similar fluorescent signals after 30  min, 
while the fluorescence intensity of cell slides treated 
Table 1 Efficiency of europium intercalation in VSOP
m(Eu):m(Fe) used  
in the synthesis [%]
m(Eu):m(Fe) found 
in the particle [%]
Eu‑VSOP‑1 1.02 0.73
Eu‑ VSOP‑2 2.05 1.25
Eu‑ VSOP‑3 3.05 1.62
Eu‑ VSOP‑4 3.79 1.88
Eu‑ VSOP‑5 5.12 2.10
Eu‑ VSOP‑6 7.65 2.18
Eu‑ VSOP‑7 10.21 2.74
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with  DELFIA® decreased after 60  min (Fig.  5C, G). 
In contrast, the fluorescent signal developed with the 
customized HEE was stable when slides were stored in 
the dark at RT for more than 60 min and at − 20 °C for 
at least 2 weeks (data not shown). Conventional detection 
of Eu-VSOP by iron stain (Fig. 5A–F) confirmed colocali-
zation of iron and fluorescent signals of Eu-VSOP-labeled 
cells and tissues, but the fluorescent signal of Eu-VSOP 
appears to be more sensitive than that of the iron stain.
Fluorescent signal measurements of 10 ROIs per image 
over time, with both enhancer solutions, confirmed that 
the Eu-fluorescent signal peaks after 30 min and remains 
stable until 60 min when the slides were incubated with 
our customized HEE and kept in the dark at RT (Fig. 5G).
To test the detectability of the Eu-fluorescent signal 
in histological spleen tissue sections, mice were intrave-
nously injected with 0.2 mmol Fe/kg of Eu-VSOP-7 and 
tissues were dissected 24  h later. This is a typical dose 
and protocol used in our previous studies with VSOP [35, 
37, 67]. When administered i.v., the particles are readily 
taken up in the spleen.
In spleen tissue sections, the fluorescence detection 
of Eu-VSOP was possible for both paraffin-embedded 
(Fig.  6) and cryosectioned tissue (not shown). Within 
a b
c d
Fig. 6 Fluorescence detection of Eu‑VSOP in tissue sections. Ex vivo detection of Eu‑VSOP in mouse spleen. 24 h after IV administration of Eu‑VSOP, 
iron (blue) was detected in splenic red pulp (a, c, Prussian blue stain with nuclear fast red counterstain). Serial section with fluorescence detection of 
europium with HEE (b, d, red staining, bright‑field background). Inset in d shows intracellular and extracellular Eu‑VSOP accumulations (arrows and 
arrowheads, respectively). Scale bar: 100 µm
Table 2 Magnetic properties of  the synthesized nanopar-
ticles
Magnetic saturation (Ms) indicates a high degree of crystallinity but, along with 
magnetic relaxivity  (R1 = T1-relaxivity,  R2 = T2-relaxivity), decreases with rising 
 Eu3+ content
R1 (L/mmol s) R2 (L/mmol s) MS  (Am
2/kg Fe)−1
VSOP 32 85 103.6
Eu‑VSOP‑1 28 74 96.5
Eu‑VSOP‑2 24 61 82.7
Eu‑VSOP‑3 24 62 86.9
Eu‑VSOP‑4 28 75 83.5
Eu‑VSOP‑5 24 65 82.2
Eu‑VSOP‑6 17 46 59.9
Eu‑VSOP‑7 19 53 69.6
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the spleen, the particles accumulated in the reticuloen-
dothelial structures of the splenic red pulp and are largely 
excluded from the lymphoid follicles, as seen by conven-
tional Prussian blue staining for iron detection (Fig. 6a, c). 
Adjacent tissue sections processed for fluorescence 
detection of Eu-VSOP show a corresponding robust 
europium signal in the red pulp, with relative absence of 
signal in the lymphoid follicles (Fig. 6b, d). Higher magni-
fication (inset in Fig. 6d) shows Eu-VSOP accumulations 
that appear to be intracellular (arrows) as well as extra-
cellular (arrowheads) compared to the bright-field image.
Discussion
Properties of the VSOP and Eu‑VSOP
Coprecipitation of iron(II) and iron(III) chloride with 
ammonia for VSOP or additionally europium(III) chlo-
ride for Eu-VSOP is a straightforward and economic 
method to synthesize stable citrate-coated iron oxide 
nanoparticles without or with Eu doping.
As expected, with increasing amounts of Eu used in the 
synthesis, the total amount of intercalated Eu increased, 
while both the efficiency of Eu intercalation and the yield 
of magnetic particles decreased (Table 1).
Consistent with published reports on other parti-
cles [68], Eu-VSOP with high europium doping showed 
reduced magnetic properties (Table  2). Likely, increas-
ing Eu concentrations during synthesis (Eu-VSOP-7) 
increases the proportion of VSOP with very high Eu con-
tent with reduced magnetism which are consequently 
lost during the magnetic separation steps.
In contrast, the hydrodynamic diameter of Eu-VSOP 
was not influenced by Eu-doping. The iron oxide core 
size of approx. 5 to 7 nm is in the same range as for VSOP 
without Eu-doping, but slightly smaller than the hydro-
dynamic diameters (in average 11 nm) as the thickness of 
the citrate coating, including the associated water mol-
ecules, is around 1.5 nm [31]. The selected areas of elec-
tron diffraction (SAED) pattern confirmed that Eu-VSOP 
maintained the cubic structure of maghemite/magnetite 
characteristic of magnetic IONP [68]. Overall, europium 
doping did not lead to fundamental structural changes 
of VSOP. This observation is consistent with previous 
reports on the doping of different IONP with various lan-
thanides in solvothermal synthesis [69].
The magnetic saturation (Ms) of VSOP indicates a 
high degree of crystallinity [11] and decreases with ris-
ing europium content (Table  2). This might be attribut-
able to distortion of the crystal lattice by the europium 
ions, which have a significantly larger radius than  Fe3+ 
ions (r(Eu3+) =  0.95 Å, r(Fe3+) =  0.55 Å). The reduced 
magnetic saturation led to decreased magnetic relaxiv-
ity  (R1 and  R2) after intercalation of lanthanides into the 
core of IONP as previously observed by others [51, 70]. 
Eu-VSOP-4 had the highest magnetic relaxivity of the 
synthesized Eu-VSOP in the current study. Although our 
previous in  vivo experiments demonstrated Eu-VSOP-7 
to have sufficient magnetic properties to produce enough 
signal for single-cell detection using T2*-weighted MR 
imaging [66], we suggest to test Eu-VSOP-4 in future 
applications.
Furthermore, VSOP with comparable magnetic prop-
erties have been detected by T2*-weighted MRI in ath-
erosclerotic plaques after nanoparticle accumulation [41, 
43].
Fluorescence of Eu‑VSOP
The europium fluorescent signal is detected by using an 
antenna system provided by the enhancer solution. As 
described by Hemmilä et al., in the case of free  Eu3+ ions, 
each  Eu3+ is coordinated by three β-NTA and two TOPO 
molecules surrounded by Triton-X100 forming a micelle 
structure (Enhancer-Eu3+) [64] (Additional file 1: Figure 
S1).
For energy transfer from the antenna to  Eu3+ ions on 
the surface of the iron oxide core of Eu-VSOP, the  Eu3+ 
ions must also be coordinated by β-NTA. Therefore, we 
suggest that a similar micellar structure might be formed 
to protect the europium ions from quenching by water 
molecules and propose a similar micelle structure for the 
fluorescent compound formed with the customized solu-
tion (Enhancer-Eu-VSOP) (Fig. 7).
Experiments comparing  DELFIA® and the custom-
ized HEE enhancer showed a linear relation between the 
concentration of  Eu3+ ions and fluorescence intensity 
(Fig. 2). Therefore, both enhancer systems are suitable for 
analytical quantification of  Eu3+ ions. However, the cus-
tomized HEE has the advantage of high buffer capacity 
(Additional file 4: Figure S2), which is important for the 
investigation of organic material that frequently needs to 
be dissolved in strong acidic solutions.
The Eu fluorescence intensity developed with the com-
mercial  DELFIA® enhancer was reduced by free  Fe3+ 
ions exceeding 1  μmol/L. In contrast Eu fluorescence 
intensity with HEE remained similarly stable in the pres-
ence of up to 100  μmol/L  Fe3+ (Fig.  3). Decreased Eu 
fluorescence intensity using  DELFIA® might be attrib-
utable to competition between europium and iron ions 
for the chelator (β-NTA). The equilibrium between these 
reactions is pH-dependent and higher pH seems to favor 
the formation of the europium-β-NTA-complex. In 
addition, higher pH leads to higher concentration of the 
deprotonated β-NTA− anion (right side of Eq. 1) result-
ing in more β-NTA− anions available for  Fe3+ and  Eu3+ 
coordination.
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To show that the fluorescence measured actually 
reflects the Eu-doped nanoparticles (Eu-VSOP) and not 
free  Eu3+ ions and to prove that Eu is intercalated into 
the nanoparticle core, a sample of Eu-VSOP was diluted 
and filtrated (10 kD filter). The Eu fluorescence of the fil-
trate was less than 0.1% of the fluorescent signal obtained 
for the Eu-VSOP solution without filtration (data not 
shown). This experiment confirms that the fluorescent 
signal measured for Eu-VSOP-7 originates form the com-
plex formed with β-NTA and TOPO.
Eu3+
O2
Fe3+
TOPO
Triton
Fig. 7 Structure of the fluorescent compound (enhancer‑Eu‑VSOP). The  Eu3+ ions located on the surface of the iron core of Eu‑VSOP are coordi‑
nated by the enhancer components. The HEE is prepared based on the antenna system formed by the chelator (β‑NTA) and the ligand (TOPO) with 
a modified buffer system. This complex is surrounded by Triton X‑100 forming a micelle. The suggested structure is based on the structure of com‑
mercial enhancers for fluorescence detection of Eu in analytical procedures as suggested by Hemmilä et al.
Therefore, the HEE with a pH of 6.6 favors the 
quantitative analysis of Eu in the presence of  Fe3+ 
ions in comparison with the commercial enhancer 
 (DELFIA®), which contains free acetic acid and has a 
pH of 2.5.
A similar reduction of Eu fluorescence intensity with 
both enhancer solutions was observed in the presence of 
 Ca2+ (data not shown). This is important for the investi-
gation of biological samples, which contain iron, calcium, 
and other metal ions.
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Longitudinal comparison of the fluorescence stability 
developed by both enhancer solutions with Eu-VSOP-7 
shows that the HEE develops a longer-lived signal inten-
sity than the one measured with the  DELFIA® enhancer, 
whose signal rapidly decreases (Fig.  4). We speculate 
that the low pH and the free acetic acid of the  DELFIA® 
enhancer lead to a further release of  Eu3+ and  Fe3+ from 
the nanoparticle core, which might increase the compl-
exation of free iron by the enhancer and decreased Eu 
fluorescent signal due to saturation of the enhancer.
To meet this concern, the use of HEE for analytical 
detection of Eu-IONP in solution should be standard-
ized for the sample of interest with a constant time, not 
shorter than 60  min, between addition of the enhancer 
and assessment of the Eu fluorescent signal. In addition, 
data should be normalized to account for variations in 
the performance of photometers.
Fluorescence detection of Eu‑VSOP in cells and tissue
In this study, we used phagocytic RAW 264.7 mac-
rophages labeled with IONP with the highest content of 
europium (Eu-VSOP-7) to compare the performance of 
both enhancer solutions when applied to cells and tissue 
sections. The RAW 264.7 cells efficiently take up both 
plain and Europium-doped VSOP.
The effect on PDT suggests that Eu-VSOP-3 and VSOP 
have slightly better biocompatibility than Eu-VSOP-7 
(Additional file 2: Figure S3) in vitro. For future applica-
tions, we prefer using Eu-VSOP-4, which has better mag-
netic characteristics for more sensitive MRI detection 
as well as better cell biocompatibility than Eu-VSOP-7 
(Table 2).
Fluorescence detection of Eu-VSOP was successful 
in cells and a higher signal stability was achieved using 
the customized HEE in comparison with the  DELFIA® 
enhancer (Fig. 5). An additional advantage of the custom-
ized enhancer is the higher stability of the europium fluo-
rescent signal 2 weeks after storage of cell slides at − 20° 
(not shown).
In spleen tissue sections, fluorescence detection of Eu-
VSOP was achieved for both paraffin-embedded (Fig. 6) 
and cryosectioned tissue (not shown). The fluorescent 
signal of Eu-VSOP-7 in spleen sections was robust and 
proved IONP accumulation in reticuloendothelial struc-
tures of splenic red pulp, as seen by conventional Prus-
sian blue staining (Fig. 6a, c).
This result proves the concept for histological detec-
tion of Eu-VSOP using fluorescence microscopy. Future 
studies could include immunofluorescence staining for 
intracellular and extracellular markers and use geneti-
cally modified animals with fluorescent reporters to 
investigate the cellular and molecular interactions with 
Eu-VSOP in more detail. Our previous studies using 
standard VSOP as a tool to investigate neuroinflamma-
tion showed evidence of both intra- and extracellular 
localization of NP in inflamed tissue, although this was 
difficult to show unambiguously with the limitations of 
conventional Prussian blue iron staining. With fluores-
cence detection of Eu-VSOP, confocal microscopy with 
3D reconstruction could be used to unambiguously con-
firm the intracellular or extracellular localization of the 
particles in both normal and abnormal tissue structures.
In conclusion, we developed stable VSOP doped with 
europium (Eu-VSOP) and a customized histo-Europium-
enhancer (HEE) solution, which, when used in conjunc-
tion with Eu-VSOP, produces fluorescent signals that can 
be detected by fluorescence microscopy in both cells and 
tissue sections. Furthermore, fluorescence detection of 
Eu-VSOP provides a stable optical tool to investigate cel-
lular and molecular interactions of Eu-VSOP.
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Additional file 1: Figure S1. Schematic illustration of the micellar 
structure formed by free  Eu3+ and HEE. The europium ion is coordinated 
by three β‑NTA molecules via the two oxygen atoms (red) of the two car‑
bonyl groups and by two TOPO molecules (green) via the oxygen atoms. 
The complex is surrounded by Triton X‑100 forming the micelle.
Additional file 2: Figure S3. Effect of nanoparticle uptake on RAW 
264.7 macrophages—population doubling time (PDT). Overall, after 4 h 
incubation (B), macrophages showed a higher uptake of VSOP, followed 
by Eu‑VSOP‑3 and Eu‑VSOP‑7; however, after 24 h incubation (D), average 
uptake was similar for all NP and ~ tenfold higher. The PDT of labeled 
and non‑labeled cells were compared using two‑way ANOVA (n = 3). 
The PDT of macrophages incubated with NP for 4 h was only significantly 
(P < 0.001) increased when incubated with Eu‑VSOP‑7 in comparison to 
Eu‑VSOP‑3 and non‑labeled cells. However, after 24 h NP incubation, cells 
labeled with all particles tested—VSOP (P < 0.01), Eu‑VSOP‑3 (P < 0.001), 
and Eu‑VSOP‑7 (P < 0.001)—showed slightly increased PDT in comparison 
with non‑labeled cells. All PDT of labeled NP gradually approached those 
of non‑labeled cells after 6 days when almost all average NP uptake (Fe/
cell) was diluted by cell division.
Additional file 3: Table S1. Hydrodynamic nanoparticle size measured 
with dynamic light scattering. Mean hydrodynamic size of VSOP doped 
with Europium (9.9 to 12.0 nm) is similar to that of nondoped VSOP 
(10.8 ± 2.8 nm), and there is a narrow distribution of mean diameters 
(PdI), confirming homogeneity of the synthesized nanoparticles.
Additional file 4: Figure S2. Improved buffer capacity of HEE. Fluores‑
cence signal of  Eu3+ remains stable with HEE solution in acidic conditions. 
Several  Eu3+ solutions with c(Eu) = 1000 nmol/L and different HCL in the 
range from 0.012 to 0.9 mol/L were prepared. 100 μL of these solutions 
were mixed with 900 μL of the enhancer solution for fluorescence detec‑
tion. The Eu fluorescence intensity of a solution without HCL was set to 
100%. The high buffer capacity of the HEE leads to a stable fluorescence 
signal with up to 0.5 mol/L of HCL.
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